

# Index

- adherent-purified-LAK-Cells (A-LAK) 30
- adhesion molecules 128, 130
- adoptive transfer 87–88
- adrenal insufficiency 56
- adrenocorticotrophic hormone (ACTH) 15
- AIDS 174
- allele specific motifs 87
- anti-CD3 stimulation 12
- Antibody Dependent Cellular Cytotoxicity (ADCC) 125
- antigen recognition 86
- antigenic stimulation 74
- apoptosis 74
- appendix carcinoma 33
- autoimmune diseases 58
- autoimmune haemolytic anaemia 11
- autoimmune reactions 11
- autoimmune thyroiditis 11
- autologous bone marrow transplantation (ABMT) 17, 110–111, 113
  - IL-2 17
  - immune dysfunction 17
- BCG 170, 172
- BCNU 101, 106, 110–111, 114
- bispecific antibody 133
- bispecific monoclonal antibody (bs-mAb) 132, 134–137
- bladder cancer 20, 172
- bone marrow transplantation 18
- breast cancer 32, 109, 115
  
- C3a 52
- carboplatin 105, 114
- carcinoid tumour 150
- CBDCA 101
- CD25 73
- CD28-B7 128
  
- CD29 128
- CD56<sup>+</sup> NK cells 11
- chimeric Ig/TCR 133–134, 136–137
- chronic myelogenous leukemia 146
- cimetidine 16
- cisplatin (DDP) 104
- cisplatin 97
- cisplatinum 39
- CML 32
- Coley, William 1, 4
- colon cancer 171
- colon carcinoma 10, 145
- colorectal 32–34
- colorectal and breast cancer 113
- colorectal cancer 39, 108, 115, 157, 170
- colorectal carcinoma 153
- complement dependent cytolysis (CDC) 125
- complement system 50–52, 62
- corticotropin 55
- corticotropin releasing hormone (CRH) 15
- cortisol 15, 55
- cyclophosphamide (CTX) 8, 16, 61, 97, 99–102, 105–109, 112–113, 115, 177
  - non specific cell-mediated cytotoxicity 97
  - suppressor T cell function 97
- cytotoxicity 77
  
- dacarbazine (DTIC) 98, 100–103, 105–106, 157
- DDP 100–101, 106, 110, 112
- desquamation 56
- dose response 141–142, 144, 158
  - IFN- $\alpha$  144
  - IFN- $\beta$  144
  - IFN- $\gamma$  144

- IL-2 144
- IL-2/IFN- $\alpha$  144
- IL-2/IFN- $\beta$  144
- IL-2/IFN- $\gamma$  144
- IL/2/IL-4 144
- IL-2/TNF 144
- doxorubicin (DOX) 97, 101, 105–106, 109, 111–114
- EBV 146
- endothelial cells 79
- Epstein-Barr virus 90
- extracellular matrix (ECM) 128
- flavone acetic acid (FAA) 100, 104
- 5-fluorouracil (5-FU) 39, 108–113, 115, 157
- gastric cancer 110–111
- gastric carcinoma 10
- gene therapy 177
- gene transduction 178
- hairy cell leukemia 146
- hepatitis B virus (HBV) 175
  - rIL-2 therapy 175
  - IFN-alpha 175
  - head and neck cancer 110, 173
- head and neck carcinoma 10
- head and neck tumours 19
- hepatocellular carcinoma 20, 113–114
- HIV 174
- HIV-associated lymphomas 174–175
- HPV16 90–91
- HPV18 90–91
- hybridoma 125
- hypoadrenalism 11
- hypocholesterolaemia 56
- hypotension 52, 61–62
- ICAM-1 131
- IL-2
  - $\alpha$ -interferon ( $\alpha$ -IFN) 105, 106, 113, 115–116, 135
  - $\alpha$ -interferon and chemotherapeutic agents 101
  - activation of cellular targets 48
  - adjuvant to vaccination 176
  - administration 98
  - and chemotherapeutic agents 95
  - and CTX 97
  - as a single agent 21, 22
  - B lymphocytes 125
  - bacteria-induced immune-suppression 170
  - BCNU 158
  - biological effects 48
  - bolus administration 14
  - CBDCA 158
  - characteristics 2
  - chemotherapeutic agents 96
  - clinical effects 48
  - continuous intravenous infusion 14
  - CTX 100–101, 105–109, 112–113, 115
  - cytokine production 76, 77
  - cytokines as mediators 48
  - cytotoxicity 76, 77
  - DDP 100–101, 104–105, 110, 112, 116, 158
  - dosage 98
  - dose dependence 13
  - dose response 141–142
  - down-regulation of the immune system 15
  - doxorubicin (DOX) 97, 105, 107, 109, 111–114
  - DTIC 100–105, 158
  - duration of therapy 15
  - FAA 104
  - 5-FU 108, 110, 115, 157–158
  - gene transduction 131
  - HBV 175
  - HIV 174
  - homing 78
  - IL-4 152
  - immune cells 77
  - immune response 130
  - immunoaugmentation 97
  - immunologic parameters 11
  - immunomodulators 96
  - interferon-alpha (IFN- $\alpha$ ) 145–146, 150–151, 155, 157–158
  - interferon- $\alpha$  combination trials 154
  - interferon-beta (IFN- $\beta$ ) 146–148, 151–152
  - interferon-gamma (IFN- $\gamma$ ) 147, 151–153
  - Interleukin-4 149, 154
  - intra-peritoneal therapy 171
  - intra-pleural therapy 171
  - intra-vesical therapy 172
  - intramuscular injections 14
  - intrathymic T-cell maturation 130
  - LAK and  $\alpha$ -IFN 136
  - LAK-cells 29–30, 100, 103–107, 113–114
  - mitogenic effect 74–75

- MMC 111
- molecular weight 2
- monotherapy 9
- monotherapy in melanoma 8
- motility 78
- natural 60, 71
- opposing secondary effects 7
- peri-tumour therapy 172
- programmed cell death (apoptosis) 74
- proliferation 77
- recombinant 60, 71
- regional application 18
- regional therapy 10
- renal cell cancer 9
- repeated treatments 16
- response-predictive power of immunologic parameters 12
- schedule and route 14
- structure/function 71
- subcutaneous injections 14–15
- susceptibility to cytotoxic agents 96
- T cell differentiation 76
- tamoxifen (TAM) 106, 158
- TNF- $\alpha$  148, 152
- toxicity 45–69
- treatment-induced immune-suppression 170
- tumour necrosis factor-alpha 153
- vascular permeability 96
- vinblastine (VBL) 107, 158
- viral infectious diseases 174
- VP-16 112
- Zidovudine (AZT) 174
- IL-2 receptor (IL-2R) 72–74, 76
  - cellular distribution 73
- immune modulation 177
- immune response 131
  - tumour cell escape 131
- immunologic parameters 11
- indomethacin 16
- interferon-alpha (IFN- $\alpha$ ) 146, 155
- interferon-beta (IFN- $\beta$ ) 147
- interleukin-4 (IL-4) 154
- intra-arterial 20
- intra-arterial infusion 10
- intrahepatic 20
- intralymphatic 10, 18
- intrapertitoneal 10, 19
- intrapertitoneal fibrosis 59
- intrapleural 10, 20, 37
- intrathecal 21
- intravesical 20
- intravesical perfusion 10
- Kaposi's sarcoma 174
- LAK activity 2–3, 74–75, 77 127
  - 144–149, 151–153
- lymphokine-activated-killer (LAK)
  - cells 29, 78, 103, 105, 114, 178
  - activity versus tumour type 39
  - DOX 97
  - endothelial cells 50
  - financial cost 39
  - IL2 38, 39
  - intravenous IL-2 32
  - mechanisms of action 30
  - regional administration 34
  - response rates and their variations 38
  - Rosenberg's schedule 31
  - systemic administration 31
  - therapeutic benefit 39
  - toxicity 34, 37
  - VLS 50
- LAK cells and IL2 34
- leptomeningeal cancer 21
- LFA 131
- LFA-1 78
- LFA-1-InterCellular Adhesion Molecule (ICAM) 128
- li chain 86
- liver metastases 20
- lung cancer 32, 111–112, 153
- Lymphocyte Function associated Antigen (LFA-3) 128
- Lymphokine Activated Natural Killer cells (LANAK) 30
- Lymphokine Activated Tumour Inhibition (LATI) 173
- lymphoma 32–34, 39, 146, 148
- lymphopenia 79
- MDM-2 91
- MEL-14 78
- melanoma 10, 13, 19, 32–34, 36, 38–39, 99–102, 113, 144, 146–148, 150, 152–154, 156–157, 177–178
- melanoma associated gene products (MAGE) 90
- melphalan 114
- mesothelioma 10, 20
- MHC class I expression 86
- MHC class I molecules 87
- MHC class II expression 86
- MHC class II molecules 87
- MHC-restriction 126
- MHC-unrestricted cytolysis 127
  - lymphocyte membrane structures 127

- natural killer (NK) lymphocytes 127
- mitomycin (MM) 115–116
- mitomycin C (MMC) 111, 113
- MOv18 mAb 134–135
- multidrug-resistant human cancer cells 95
- multidrug-resistant tumour cells 116
  
- neuroblastoma 33, 113–114
- NHL 32
- nitric oxide 53–54
- NK cell stimulatory factor (NKCSF) 75
- non-Hodgkin's lymphoma 153
- non-steroidal anti-inflammatory drugs (NSAID's) 54
  
- ovarian cancer 32–33, 133–135, 171
  - Bs-mab 134
- ovarian carcinoma 10, 19
  
- p53 90–91
- pemphigus vulgaris 56
- peptide vaccination 89
- peritumoural 10, 19
- phospholipase-A2 50–51
- pleural mesothelioma 171
- polyethylene glycol 14
- prostaglandin synthesis inhibitors 16
- pruritus 56
  
- quality of life 156–157, 179
  
- RCC 10, 115–116
- recombinant human interferon-gamma (IFN- $\gamma$ ) 151
- regional administration 171
- renal 32–34
- renal adenocarcinoma 35
- renal cancer 135, 151–152
- renal carcinoma 150
- renal cell cancer 9, 38–40, 106, 113, 136, 154, 179
- renal cell carcinoma 10, 13, 37, 107, 146, 153, 155, 177
- risk/benefit ratio 179
  
- sarcoma 32, 34, 39, 113, 115, 144–145, 147–150, 172, 173
- septic shock 45, 50–53
- signal transduction 72–73
- sudden death 51
- suppressive factors 10
- suppressor cells 10
  
- T cell growth factor (TCGF) 2
- T cell receptor (TCR) 74, 126
- T<sup>c</sup> epitope 89
- T<sup>H</sup> epitope 89
- TAA 131–133, 137
- thromboxane A2 50, 53
- thymocyte maturation 76
- thyroid carcinoma 33
- thyroid dysfunction 55
- granulocyte-monocyte-colony stimulating factor (GM-CSF) 55
- Tumour Infiltrating Lymphocytes (TIL) 11, 40, 85, 88, 178
  - breast cancer 178
  - colon cancer 178
  - gene for Tumour Necrosis Factor (TNF) 178
  - gene modified 178
  - lymphomas 178
  - melanoma 178
- TNF 12, 13
- TNF levels 78
- total body irradiation 114
- toxicity 34, 99, 101–112, 114, 148, 151, 153–154, 156, 175, 178–179
  - cardiac 62
  - cardiovascular 51
  - chills 58, 63
  - coagulation disturbances 57
  - constitutional symptoms 58, 63
  - development of antibodies 60
  - endocrinologic 55
  - fever 58, 63
  - gastro-intestinal 54, 63
  - haematologic 57
  - hepatic 54
  - hypotension 62
  - IL2 + IFN + LAK 37
  - IL-2 + IFN $\alpha$  high dose i.v. 46–47
  - IL-2 + IFN $\alpha$  low dose s.c. 46–47
  - IL2 + LAK 37
  - IL-2 + LAK cont. infusion 46–47
  - IL-2 + LAK high dose i.v. 46–47
  - IL-2 + LAK low dose bolus i.v. 46–47
  - IL-2 alone high dose i.v. 46–47
  - infection 58, 62
  - intravenous therapy 156
  - LAK cells and IL-2 34
  - life threatening 63
  - mechanisms 48
  - metabolic 55
  - mode of administration 59
  - mortality 60
  - mucocutaneous 56
  - nephrotoxicity 53

- neurologic 57
- neurotoxicity 62
- promotion of tumour growth 59
- pruritus 63
- pulmonary 53, 62
- subcutaneous injections 60
- subcutaneous therapy 156
- symptomatic management 62
- transendothelial migration 14
- tumour associated antigens 129
- tumour necrosis factor (TNF)-R 75
- tumour necrosis factor-alpha (TNF- $\alpha$ ) 153
- tumour specific antigens 129
- tumour specific T-cells 90
- urinary bladder carcinoma 10
- vascular leak syndrome (VLS) 45, 49, 51, 53–54, 57, 61–63
- vinblastine (VBL) 107
- Very Late Antigen (VLA) 128
- vincristine 114
- vitiligo 11
- VM-26 114
- VP-16 112
- YAC-lymphoma 146